Name: Estrella Immunopharma, Inc. (ESLA) Cash Flow Statement
Creator: FinSpry

Estrella Immunopharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Estrella Immunopharma, Inc. (ESLA) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Jun 2023	Jun 2022	Jun 2021
Operating Activities
Net Income	-8.85	-11.11	-1.69	-0.73
Stock Based Compensation	0.00	0.41	0.13	0.06
Change in Working Capital	0.78	9.37	0.11	0.00
Change in Accounts Payable	-0.07	8.39	0.00	0.00
Change in Other Working Capital	0.85	0.98	0.11	0.00
Other Operating Activities	0.51	0.00	0.00	0.00
Net Cash from Operating Activities	-7.64	-1.34	-1.44	-0.67
Investing Activities
Capital Expenditures	0.00	0.00	0.00	0.00
Other Investing Activities	0.00	-0.27	0.00	0.00
Net Cash from Investing Activities	0.00	-0.27	0.00	0.00
Financing Activities
Debt Repayment	-10.00	0.00	0.00	0.00
Common Stock Issued	0.08	0.00	0.02	0.00
Common Stock Repurchased	-0.57	0.00	0.00	0.00
Other Financing Activities	9.58	0.00	0.52	0.67
Net Cash from Financing Activities	-0.49	0.00	5.53	0.67
Summary
Net Change in Cash	-8.13	-1.61	4.09	0.00
Cash at Beginning of Period	9.05	4.09	0.00	0.00
Cash at End of Period	0.92	2.48	4.09	0.00
Free Cash Flow	-7.64	-1.34	-1.44	-0.67
Supplemental Disclosures
Interest Paid	0.00	0.00	0.00	0.00
Income Taxes Paid	0.00	0.00	0.00	0.00